Top Medical News
Elvira Manzano, an hour ago
A new guideline on when to deprescribe proton pump inhibitors (PPIs) in the setting of gastroesophageal reflux disease (GERD) and other upper gastrointestinal (GI) symptoms will guide clinicians’ treatment decisions amid increasing concerns over PPI overuse.
Stephen Padilla, 11 hours ago
It appears that prescribing immediate antibiotics does not lessen major adverse outcomes of subsequent hospital admission or death for young people and adults with uncomplicated lower respiratory tract infection, a recent study has shown.
Roshini Claire Anthony, 21 hours ago

Adalimumab at a dose of 0.8 mg/kg appears to be effective in treating children and adolescents with severe plaque psoriasis with no new safety risks, according to a recent phase III trial. 

Jairia Dela Cruz, Yesterday
Patients with stable schizophrenia may benefit from long-term antipsychotic treatment, with a recent meta-analysis finding that continuation of antipsychotics over a 1-year period significantly reduces symptom exacerbation in this population in contrast to a trajectory of continuous symptom exacerbation in patients on placebo.
Yesterday
Exposure to statins may lower the risk of hepatic decompensation and mortality, as well as reduce portal hypertension, in patients with chronic liver diseases (CLDs), according to a systematic review and meta-analysis.
Roshini Claire Anthony, Yesterday

Timely and active treatment for bloodstream infections caused by carbapenemase-producing Enterobacteriaceae (CPE) is associated with lower mortality risk, according to a recent study. Moreover, only patients with a high risk of death appear to benefit from combination therapy. 

Yesterday
Temporary discontinuation of methotrexate (MTX) appears to improve the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA), according to a study.
Special Reports
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
13 Mar 2017
With the drive to share the current healthcare expert’s practices in managing different types of infections, Mundipharma conducted its 1st PLUS (Pharmacy cLinical UpdateS) Summit by inviting a group of consultants to share the role of povidone-iodine (PVP-I) in infection prevention and management with the community pharmacists on 15th–16th October 2016 in Port Dickson.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
16 Dec 2016
ESMYA – Ulipristal acetate 5 mg tab – Zuellig Pharma
Conference Reports
Christina Lau, 10 May 2017

The use of granulocyte colony stimulating-factor (G-CSF) is safe in patients with limited-stage small-cell lung cancer (SCLC) treated with chemoradiotherapy, according to a post hoc analysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) 2017.

Christina Lau, 09 May 2017

Ensartinib, a small-molecule ALK tyrosine kinase inhibitor (TKI), has demonstrated intracranial response in patients with ALK-positive non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastases.

Christina Lau, 09 May 2017

Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.

Elvira Manzano, 05 Apr 2017
Treatment with sodium- glucose cotransporter 2 (SGLT-2) inhibitors reduces the risk of hospitalization for heart failure (hHF) and death compared with other glucose-lowering drugs, the retrospective, observational CVD-REAL* study has shown.
Elvira Manzano, 31 Mar 2017
Adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to statin therapy to further lower bad cholesterol does not cause memory loss or other cognitive issues in patients with known cardiovascular disease (CVD), the EBBINGHAUS* trial has shown, giving clinicians some sense of reassurance.
Pearl Toh, 30 Mar 2017
The everolimus-eluting bioresorbable vascular scaffold (BVS), Absorb, was noninferior to Xience metal stent for target lesion failure (TLF) by 1 year and between 1–2 years, but was associated with significantly higher cumulative TLF rates by 25 months, according to the ABSORB III trial presented at the ACC.17 in Washington, DC, US.
Roshini Claire Anthony, 28 Mar 2017

The use of uninterrupted dabigatran before, during, and after catheter ablation in patients with atrial fibrillation (AF) resulted in fewer major bleeding complications than uninterrupted warfarin, according to results of the RE-CIRCUIT* trial.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD